Sandoz Group AG | Finanzwire

Basculer en Français

9704	Companies
193525	Keywords
124772	Articles
103020	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 01/14/2026 at 12:05, 6 days 11 hours ago

Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment

European Commission Biosimilars Diabetes Treatment Ondibta® Approval Sandoz Strategy
PRESS RELEASE

published on 01/14/2026 at 12:00, 6 days 11 hours ago

Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes. Expected launch by early 2027

Diabetes European Commission Biosimilars Sandoz Ondibta
BRIEF

published on 01/12/2026 at 15:05, 8 days 8 hours ago

Sandoz Unveils Strategy for 'Golden Decade' of Affordable Medicines

Market Strategy Biosimilars Sandoz Group AG Golden Decade Affordable Medicines
PRESS RELEASE

published on 01/12/2026 at 15:00, 8 days 8 hours ago

Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity
Sandoz CEO to outline plans for capturing the unprecedented 'golden decade' of affordable medicines opportunity at the 44th Annual J.P. Morgan Healthcare Conference

CEO Sandoz J.P. Morgan Healthcare Conference Golden Decade Affordable Medicines
BRIEF

published on 12/08/2025 at 07:05, 1 month 12 days ago

Sandoz Acquires Just-Evotec Biologics EU SAS to Boost Biosimilar Leadership

Acquisition Healthcare Biosimilars Sandoz Group AG Continuous Manufacturing
PRESS RELEASE

published on 12/08/2025 at 07:00, 1 month 12 days ago

Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership. Expands capabilities for biosimilars with cutting-edge technology

Acquisition Biosimilars Sandoz Just-Evotec Biologics EU SAS Continuous-manufacturing Technology
BRIEF

published on 12/01/2025 at 07:05, 1 month 19 days ago

Sandoz Launches Denosumab Biosimilars in Europe

Bone Health Sandoz Denosumab Biosimilars Wyost® Jubbonti®
PRESS RELEASE

published on 12/01/2025 at 07:00, 1 month 19 days ago

Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment options for cancer-related bone disease and osteoporosis. The European launch marks a key milestone in Sandoz's growth strategy

Europe Biosimilars Cancer Osteoporosis Sandoz
BRIEF

published on 11/24/2025 at 07:05, 1 month 26 days ago

Sandoz Launches Afqlir® in Europe for Retinal Diseases

Biosimilars Retinal Diseases Sandoz Europe Launch Afqlir®
PRESS RELEASE

published on 11/24/2025 at 07:00, 1 month 26 days ago

Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases. Afqlir® matches reference medicine in efficacy, safety, and pharmacokinetics, reinforcing Sandoz commitment to patient access

Retinal Diseases Sandoz Aflibercept Afqlir European Launch

Accesswire

Published on 01/20/2026 at 23:35, 8 minutes ago

Further Shallow High-Grade Assays Infill Tunkillia S1/2 Pits
Published on 01/20/2026 at 23:30, 13 minutes ago

Correction to Press Release Issued on January 16, 2026 Announcing Closing of $976,000 Non-Brokered Private Placement
Published on 01/20/2026 at 23:20, 23 minutes ago

Pathfinder Ventures Announces $2 Million Non-Brokered Private Placement
Published on 01/20/2026 at 23:00, 43 minutes ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Due Diligence Review
Published on 01/20/2026 at 23:00, 43 minutes ago

BE Resources Announces Changes to Management

View all ACCESSWIRE

EQS Group

Published on 01/20/2026 at 20:00, 3 hours 43 minutes ago

Purchase of all outstanding Bell Group N.V. notes CH0005575151, GB0040901711 and XS0000001247
Published on 01/20/2026 at 19:19, 4 hours 23 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares – conclusion and extension of buyback programme
Published on 01/20/2026 at 18:05, 5 hours 38 minutes ago

PRC-Saltillo Announces Acquisition of Therapy Box® Apps, Enhancing AAC Communication Options Worldwide
Published on 01/20/2026 at 16:15, 7 hours 28 minutes ago

Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
Published on 01/20/2026 at 16:00, 7 hours 43 minutes ago

Orion Innovation Recognized in Connected Product Engineering Services, Q4 2025 Analyst Evaluation

Les Echos

Published on 01/20/2026 at 17:59, 5 hours 44 minutes ago

Statement of transactions in own shares from January 14, 2026 to January 16, 2026
Published on 01/20/2026 at 17:45, 5 hours 58 minutes ago

Change in Baikowski® executive management
Published on 01/20/2026 at 07:30, 16 hours 13 minutes ago

Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy
Published on 01/19/2026 at 17:45, 1 day 5 hours ago

Financial communication calendar 2026
Published on 01/19/2026 at 17:35, 1 day 6 hours ago

EURAZEO ENTERS INTO AN EXCLUSIVE AGREEMENT WITH L CATTERTON FOR THE SALE OF ITS MINORITY STAKE IN EX NIHILO

View all LES ECHOS COMFI WIRE